177 related articles for article (PubMed ID: 37219599)
1. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
4. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
6. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
Ho CL; Kurman RJ; Dehari R; Wang TL; Shih IeM
Cancer Res; 2004 Oct; 64(19):6915-8. PubMed ID: 15466181
[TBL] [Abstract][Full Text] [Related]
7. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
12. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.
Verbruggen MB; Sieben NL; Roemen GM; Rockx DA; van Diest PJ; Verheijen RH; Dorsman JC
Int J Gynecol Cancer; 2009 Dec; 19(9):1560-3. PubMed ID: 19955937
[TBL] [Abstract][Full Text] [Related]
13. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
14. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
15. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
16. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
17. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic analysis of ovarian serous cystadenomas.
Cheng EJ; Kurman RJ; Wang M; Oldt R; Wang BG; Berman DM; Shih IeM
Lab Invest; 2004 Jun; 84(6):778-84. PubMed ID: 15077125
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
20. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.
Xu Y; Bi R; Xiao Y; Tu X; Li M; Li A; Shan L; Zhou S; Yang W
Diagn Pathol; 2017 Dec; 12(1):87. PubMed ID: 29273082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]